<DOC>
	<DOCNO>NCT01220999</DOCNO>
	<brief_summary>This clinical trial CS-1008 humanize monoclonal antibody . This trial explore CS-1008 distributes body , activity CS-1008 patient metastatic colorectal cancer . The purpose study give patient metastatic colorectal cancer series different CS-1008 antibody dose order : - Study dose CS-1008 effect CS-1008 distributes body ( biodistribution ) , long circulates blood ( pharmacokinetics ) much attach tumour ( tumour uptake ) . These issue study initial infusion 111In-CS-1008 ( CS-1008 tag small amount radioactive Indium - also call Indium-111 111In ) , also cycle weekly infusion CS-1008 antibody . - Study change function ( metabolism ) tumour cell follow CS-1008 administration . - Assess whether repeat dos CS-1008 cause shrinkage tumour . - Study whether experimental treatment CS-1008 change chemical blood may indicate tumour cell death ( serum apoptosis biomarkers ) and/or tumour response treatment ( serum tumour biomarkers ( CEA - carcinoembryonic antigen ) ) .</brief_summary>
	<brief_title>An Imaging Pharmacodynamic Trial CS-1008 Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This clinical trial laboratory produce humanised monoclonal antibody call CS-1008 . CS-1008 bind receptor find cancer cell call death receptor 5 ( DR5 receptor ) , stimulate , cause cancer cell destroy process call apoptosis . CS-1008 could important potential therapeutic patient colorectal cancer cancer . The purpose study : - Primarily - Determine influence CS-1008 dose initial biodistribution , pharmacokinetics tumour uptake 111-In-CS-1008 ( CS-1008 tag small amount radioactive Indium - also call Indium-111 ) follow single infusion CS-1008 , determine change parameter follow continuous sequential dos CS-1008 . - Secondarily - Determine change tumour metabolism follow CS-1008 administration - Describe anti-tumour response CS-1008 metastatic colorectal cancer . - Determine change serum apoptosis biomarkers serum tumour response marker follow treatment CS‐1008 . Research design method : This non-randomised , open label , single site ( Austin Hospital ) , dose cohort study CS-1008 patient advance colorectal carcinoma receive least one previous regimen chemotherapy treatment metastatic disease . Consenting , eligible patient receive course seven dose CS-1008 , give weekly intravenous ( IV ) infusion 30 minute . The initial infusion CS-1008 trace label Indium-111 ( 111In-CS-1008 ) . Ten 25 patient treated cohort allocate initial sequential weekly dos CS-1008 assess . Each five dose level cohort make two patient expandable five patient additional information biodistribution and/or pharmacokinetics cohort dose require . The initial 111In-CS-1008 dose follow gamma camera image biodistribution tumour uptake study blood sample 10 day period evaluate pharmacokinetics serum biomarkers . Weekly infusion CS-1008 subsequently occur . The day 36 infusion CS-1008 also trace label 111In , subsequent gamma camera image biodistribution tumour uptake blood sample pharmacokinetics serum apoptosis biomarkers . Patients reassess disease status ( RECIST v1.1 ) , serum tumour biomarkers ( CEA - carcinoembryonic antigen ) development human-anti-CS-1008-antibody development ( HAHA ) day 44-50 ( end cycle/study visit ) . Patients assess change tumour metabolism follow CS-1008 administration 18F-FDG PET/CT scan baseline , day 15 end cycle one . Patients stable disease well day 44-50 reassessment may continue weekly CS-1008 disease progression absence unacceptable toxicity patient treat physician request cessation treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically prove metastatic colorectal cancer one target lesion ≥2cm evaluable gamma camera imaging . If lesion previously irradiate , must document progression follow radiotherapy . Received least one prior course chemotherapy metastatic disease . Expected survival least 3 month . ECOG Performance Status ≤2 Age ≥ 18 year old . Able willing give write informed consent . Within last 1 week prior first study drug administration , laboratory parameter vital function normal range . Non clinically significant laboratory abnormality generally permit , except follow must within range specify : Neutrophils ≥ 1.5 x 10^9/L Platelets ≥ 90 x 10^9/L INR ≤ 1.5 Serum bilirubin ≤ 1.5 x ULN AST ( SGOT ) , ALT ( SGPT ) ≤ 2 x normal upper limit ( ≤ 5 x ULN liver metastasis ) Calculated creatinine clearance ≥ 55mL/min ( CockcroftGault formula ) Active central nervous system metastasis . Definitively treated metastasis allow stable 6 week therapy . Known immunodeficiency HIV positivity . Serious illness e.g . serious infection require antibiotic , bleed disorder , condition opinion Investigator would interfere ability patient fulfill study requirement . Other malignancy , except nonmelanoma skin cancer , within 3 year prior first study drug administration , opinion investigator &gt; 10 % risk relapse within 12 month . Chemotherapy , radiotherapy investigational agent within 4 week prior first study drug administration . Regular corticosteroid , NSAID ( paracetamol lowdose aspirin ) immunosuppressive treatment within 3 week prior first drug administration . Intermittent dose corticosteroid NSAID permit less 4 dos within 3 day period . Mental impairment may compromise ability give informed consent comply requirement study . Lack availability clinical followup assessment . Pregnancy breastfeed . Women childbearing potential : refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>CS-1008 mAb</keyword>
	<keyword>monoclonal antibody CS-1008</keyword>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>apoptosis</keyword>
	<keyword>caspase</keyword>
</DOC>